OBJECTIVE
Ibandronic acid (IA) is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis (1) . It may also be used for hypercalcemia treatment (elevated blood calcium levels) (2) . Arthralgia, femur fracture, pain in extremity, diarrhea, myalgia, nausea, back pain, pain, and bone pain are most common adverse events of the IA Although the day after the erythematous area had increased to 5-6 cm and the symptoms worsened, so she revisited the outcome clinic ( Figure 2 ). Also, she had a complaint of vomiting and diarrhea. At that moment she was recommended to apply topical hydrocortisone ointment twice a day and cooling with ice packets. Her lesion was healed in two weeks. We have considered continuing her treatment with oral ibandronic acid instead of IV application. But we could not find a right answer for "How soon after the new medication must be started after this event?". Administration reports a percentage of IA patients is 0.0900%, where injection site extravasation is a detailed side effect (7) . Also, 0.03% of Zoledronic acid patients reported having extravasation as a side effect (7, 8) .
Extravasation is an infrequent side effect of the I.V.
bisphosphonates. Following the guidelines are given below for minimizing the risk of extravasations is vital to prevent this undesired situation. The author declares no conflict of interest.
Guidelines for minimizing the risk of extravasation (3)
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